L. Prudkin

发表

Prognostic Significance of Combinations of RNA-Dependent Protein Kinase and EphA2 Biomarkers for NSCLC

J. Roth, I. Wistuba, S. Swisher, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-in-human phase I study evaluating the safety, pharmacokinetics (PK), and intratumor pharmacodynamics (PD) of the novel, oral, ATP-competitive Akt inhibitor GDC-0068.

C. Jones, J. Baselga, J. Tabernero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cyclin E amplification/overexpression is associated with poor prognosis in gastric cancer.

J. Tabernero, M. Alsina, M. Scaltriti, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Anti-tumor activity of the Hsp90 inhibitor IPI-504 in HER2 positive trastuzumab-resistant breast cancer.

J. Baselga, V. Serra, K. West, 2011 .

A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors

J. Baselga, J. Tabernero, J. Hardwick, 2011, Clinical Cancer Research.

Cancer Therapy : Clinical A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab ( MK-0646 ) , an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody , in Patients with Advanced Solid Tumors

J. Tabernero, S. Cosimo, J. Hardwick, 2011 .

Proteomics-based identification of proteins secreted in apical surface fluid of squamous metaplastic human tracheobronchial epithelial cells cultured by three-dimensional organotypic air-liquid interface method.

R. Lotan, W. Hong, I. Wistuba, 2007, Cancer research.

Three-Dimensional Organotypic Air-Liquid Interface Method Tracheobronchial Epithelial Cells Cultured by Apical Surface Fluid of Squamous Metaplastic Human Proteomics-Based Identification of Proteins Secreted in

R. Lotan, W. Hong, I. Wistuba, 2007 .

miR-93, miR-98, and miR-197 Regulate Expression of Tumor Suppressor Gene FUS1

John D. Minna, Alexander Pertsemlidis, Lin Ji, 2009, Molecular Cancer Research.

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.

W. Hahn, J. Baselga, S. Kim, 2013, The Journal of clinical investigation.

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

C. Cordon-Cardo, J. Baselga, K. Marks, 2017, Nature.

TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma.

J. Baselga, M. Poca, J. Sahuquillo, 2010, Cancer cell.

Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.

J. Baselga, P. Nuciforo, M. Piccart-Gebhart, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.

R. Bernards, N. Schultz, C. Sotiriou, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract C114: Clinical response to a lapatinib-based therapy of a Li-Fraumeni Syndrome patient with a novel HER2-V659E mutation.

J. Baselga, E. Felip, P. Nuciforo, 2013 .

Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.

X. Puente, J. Baselga, E. Felip, 2013, Cancer discovery.

Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068

G. Hampton, J. Baselga, J. Tabernero, 2013, Clinical Cancer Research.

Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer

J. Baselga, M. Scaltriti, V. Serra, 2011, Molecular Cancer Therapeutics.

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

Sarat Chandarlapaty, Violeta Serra, Maurizio Scaltriti, 2011, Proceedings of the National Academy of Sciences.

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

S. Chandarlapaty, J. Baselga, N. Rosen, 2011, Oncogene.

HER 2-Positive Trastuzumab-Resistant Breast Cancer Antitumor Activity of the Hsp 90 Inhibitor IPI-504 in Updated

M. Scaltriti, V. Serra, K. West, 2011 .

Therapeutic Discovery Antitumor Activity of the Hsp 90 Inhibitor IPI-504 in HER 2-Positive Trastuzumab-Resistant Breast Cancer

M. Scaltriti, V. Serra, K. West, 2011 .

Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor

S. Chandarlapaty, J. Baselga, H. Gómez, 2010, Clinical Cancer Research.

Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic

P. Nuciforo, L. Prudkin, 2014, Cellular Oncology.

Germ-line and somatic presentations of the EGFR T790M mutation in lung cancer.

I. Wistuba, Ximing Tang, L. Prudkin, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Epidermal growth factor receptor and K‐Ras mutations and resistance of lung cancer to insulin‐like growth factor 1 receptor tyrosine kinase inhibitors

Edward S. Kim, S. Lippman, W. Hong, 2012, Cancer.

Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development.

Edward S. Kim, Y. Miller, S. Lippman, 2009, Cancer research.

Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications.

I. Wistuba, L. Prudkin, 2006, Annals of diagnostic pathology.

Immunohistochemical Expression of Estrogen and Progesterone Receptors Identifies a Subset of NSCLCs and Correlates with EGFR Mutation

I. Wistuba, J. Lee, C. Behrens, 2009, Clinical Cancer Research.

Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1α in non-small cell lung cancer cells

J. Minna, A. Gazdar, I. Wistuba, 2010, Oncogene.

EphA2 in the Early Pathogenesis and Progression of Non–Small Cell Lung Cancer

I. Wistuba, C. Behrens, L. Solis, 2009, Cancer Prevention Research.